IPP Bureau
KIMS posts Q3 FY24 consolidated PAT at Rs. 71.84 Cr
By IPP Bureau - February 05, 2024
KIMS has reported total income of Rs. 609.091 crores during the period ended December 31, 2023
Mandaviya inaugurates 24 health infrastructure facilities across AIIMS
By IPP Bureau - February 05, 2024
Delivers keynote address at the 4th convocation of AIIMS Jodhpur
DPIIT recognises 1, 17,254 startups as on Dec 2023
By IPP Bureau - February 03, 2024
At least one recognised startup in every State and UT; spread across over 80% of districts
Abbott India posts Q3 FY24 PAT at Rs. 310.98 Cr
By IPP Bureau - February 03, 2024
Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023
Thyrocare Technologies posts Q3 FY24 consolidated PAT at Rs. 15.35 Cr
By IPP Bureau - February 03, 2024
Thyrocare Technologies has reported total income of Rs. 137.47 crores during the period ended December 31, 2023
Dr Lal Path Labs posts Q3 FY24 consolidated PAT at Rs. 81.3 Cr
By IPP Bureau - February 03, 2024
Dr. Lal Path Labs has reported total income of Rs. 557.2 crores during the period ended December 31, 2023
GMM Pfaudler posts Q3 FY24 consolidated PAT at Rs. 31.72 Cr
By IPP Bureau - February 03, 2024
GMM Pfaudler has reported total income of Rs. 848.28 crores during the period ended December 31, 2023
Industry’s reaction to Union Budget 2024-25
By IPP Bureau - February 02, 2024
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Max Healthcare Institute Ltd Q3 FY24 consolidated profit up at Rs. 289.34 Cr
By IPP Bureau - February 02, 2024
Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023
Dabur India posts Q3 FY24 consolidated PAT at Rs. 514.22 Cr
By IPP Bureau - February 02, 2024
Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023
Vimta Labs posts Q3 FY24 consolidated PAT at Rs. 10.13 Cr
By IPP Bureau - February 02, 2024
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr
By IPP Bureau - February 02, 2024
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
Mankind Pharma reports 55% YoY growth in PAT for Q3 FY24
By IPP Bureau - February 01, 2024
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Glenmark partners Pfizer to launch Abrocitinib in India
By IPP Bureau - February 01, 2024
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Zydus Lifesciences launches Rexigo
By IPP Bureau - February 01, 2024
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
